Your browser doesn't support javascript.
Hydroxychloroquine: A review of its safety and efficacy in COVID-19.
Karia, Rutu H; Nagraj, Sanjana; Gupta, Ishita; Barua, Amit; Kaur, Nirmaljot; Singh, Harmandeep.
  • Karia RH; Anna Medical College and Research Centre, Mauritius.
  • Nagraj S; Internal Medicine, Jacobi Medical Centre/Albert Einstein College of Medicine, New York, USA.
  • Gupta I; Dr. Rajendra Prasad Government Medical College, Tanda, Himachal Pradesh, India.
  • Barua A; Institute of Applied Health Sciences, Chattogram, Bangladesh.
  • Kaur N; Sri Guru Ramdas Institute of Medical Sciences and Research, Amritsar, Punjab, India.
  • Singh H; Sri Guru Ramdas Institute of Medical Sciences and Research, Amritsar, Punjab, India.
J Family Med Prim Care ; 10(3): 1124-1133, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1218670
Semantic information from SemMedBD (by NLM)
1. hydroxychloroquine ADMINISTERED_TO Patients
Subject
hydroxychloroquine
Predicate
ADMINISTERED_TO
Object
Patients
2. hydroxychloroquine TREATS Transplant Recipients
Subject
hydroxychloroquine
Predicate
TREATS
Object
Transplant Recipients
3. hydroxychloroquine ADMINISTERED_TO Patients
Subject
hydroxychloroquine
Predicate
ADMINISTERED_TO
Object
Patients
4. hydroxychloroquine TREATS Transplant Recipients
Subject
hydroxychloroquine
Predicate
TREATS
Object
Transplant Recipients
ABSTRACT
SARS-CoV-2 is a novel virus that has infected millions of people across the world. Given the compelling need to develop a therapeutic strategy, hydroxychloroquine has been advocated as an effective drug for the infection. However, multiple clinical trials conducted using hydroxychloroquine have yielded contrasting results. An electronic search using the primary databases from WHO, PubMed and Google Scholar was performed that yielded 21 studies eligible for inclusion. Among a total of 1,350 patients who received hydroxychloroquine, 689 (51.04%) were females. The most commonly reported comorbidities include hypertension (15.18%), diabetes mellitus (8.44%) and pulmonary disease (8.96%). Of the hydroxychloroquine-treated patients, 70% were virologically cured compared to 12.5% of the control group (p = 0.001). A good clinical outcome with virological cure was reported in 973 patients (91%) within 10 days out of 1,061 hydroxychloroquine-treated patients. A total of 29 (65%) renal transplant recipients achieved complete recovery following hydroxychloroquine administration. A total of 37 (2.7%) patients reported QT prolongation. Hydroxychloroquine was found to reduce mortality in healthy, SARS-Cov-2 positive patients and improve clinical recovery in renal transplant recipients. However, a definitive conclusion regarding its effect on viral clearance can only be reached by conducting more clinical trials involving bigger and diverse samples.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Reviews Language: English Journal: J Family Med Prim Care Year: 2021 Document Type: Article Affiliation country: Jfmpc.jfmpc_1961_20

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Reviews Language: English Journal: J Family Med Prim Care Year: 2021 Document Type: Article Affiliation country: Jfmpc.jfmpc_1961_20